Home - Atea Pharmaceuticals

HCV

Regimen of bemnifosbuvir / ruzasvir

The regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor and ruzasvir, an NS5A inhibitor, is advancing in a global Phase 3 development program for the treatment of hepatitis C virus (HCV). In a global Phase 2 study, the regimen met its primary endpoints of efficacy and safety. As single agents, both bemnifosbuvir and ruzasvir have demonstrated potent pan-genotypic antiviral activity against HCV.

ABOUT BEMNIFOSBUVIR / RUZASVIR REGIMEN

ATEA PHARMACEUTICALS

Combining innovative discoveries with development expertise to advance antivirals with the potential to transform treatments for patients with serious viral diseases.

Atea is a clinical stage biopharmaceutical company working to address unmet medical needs with innovative oral antiviral therapies.

Advancing Oral Antiviral Therapies with Multibillion Dollar Market Opportunities

Hepatitis C (HCV)

Innovative Therapies to Address Unmet Medical Needs

Hepatitis C (HCV)

Our science.

Leveraging our deep understanding of antiviral drug development, medicinal chemistry, biology, biochemistry and virology, we are discovering and developing novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Currently, we are focused on the development of orally-available direct-acting antiviral agents for the treatment of hepatitis C virus (HCV).

A network of hubs and spokes is suspended, representing the idea of a modular platform.

NEWS

Follow our progress.

Updates on the regimen of bemnifosbuvir and ruzasvir for the treatment of HCV and

other Atea news.

November 7th, 2025

Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

Company Hosting Virtual KOL Panel Event Thursday, November 13th at 10:00 AM ET BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics

November 5th, 2025

Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference

October 22nd, 2025

Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025

BOSTON, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a virtual key

All News & Press Releases

Committed to the discovery, development and commercialization of oral direct-acting antiviral therapies.

HCV